GOODMAN AND GILMAN'S THE
PHARMACOLOGICAL BASIS OF
THERAPEUTICS
14TH EDITION
• AUTHOR(S)LAURENCE BRUNTON;
BJORN KNOLLMANN
TEST BANK
1⃣
Reference
Ch. 1 — Drug Discovery: From Medicinal Plants to Computer-
Aided Drug Design
Stem
A translational research team identifies a bioactive alkaloid
from a rainforest plant that shows potent inhibition of a cancer
cell line in vitro. As the team plans next steps, they must decide
between proceeding with isolation and derivatization of the
,natural product versus moving to high-throughput screening
(HTS) of synthetic libraries. Which approach best balances
target validation, chemical tractability, and the risk of later-
stage attrition?
Options
A. Prioritize isolation and systematic derivatization of the
natural product because natural-product scaffolds are
inherently drug-like and lower attrition.
B. Prioritize HTS of diverse synthetic libraries because HTS is
faster and more likely to yield high-affinity, patentable scaffolds.
C. Use the natural product as a pharmacophore template to
perform structure–activity guided optimization plus parallel
screening of small focused libraries.
D. Abandon the natural product and perform phenotypic
screening on unrelated cell lines to find better starting points.
Correct answer
C
Rationales
Correct (C): Combining the natural product as a pharmacophore
template with focused library screening preserves the validated
biological activity while addressing chemical tractability and
patentability. This hybrid strategy leverages structure–activity
relationships (SAR) to optimize potency and ADMET while
reducing the risk of developing an intractable scaffold.
A: Overstates the assumption that natural scaffolds are always
drug-like; many natural products have poor bioavailability or
,synthetic accessibility, increasing attrition.
B: HTS alone ignores the validated bioactivity and may produce
hits that lack the natural product’s mechanistic relevance; also,
HTS hits often require heavy optimization.
D: Abandoning a validated bioactive compound sacrifices
known mechanism and increases development risk; phenotypic
screens are useful but not a reason to discard a validated lead.
Teaching point
Natural products + pharmacophore-guided optimization
combine validation with chemical tractability.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
2️⃣
Reference
Ch. 1 — Drug Discovery: From Medicinal Plants to Computer-
Aided Drug Design
Stem
A biotech firm uses target-based screening against a kinase
implicated in inflammatory disease. Several nanomolar
inhibitors are discovered, but cellular efficacy is poor due to
limited cell permeability. The medicinal chemist suggests
designing prodrugs to improve intracellular delivery. Evaluate
, the appropriateness of a prodrug strategy versus optimizing
physicochemical properties directly.
Options
A. Prodrug design is preferable because it bypasses the need to
modify the active pharmacophore, preserving potency.
B. Directly optimizing lipophilicity and polar surface area of the
active compound is preferable to improve permeability and
avoid prodrug complexity.
C. Use a prodrug only if the compound is rapidly metabolized;
otherwise, modify the target instead.
D. Abandon small-molecule approaches and pursue monoclonal
antibodies against the kinase.
Correct answer
B
Rationales
Correct (B): Direct optimization of lipophilicity and polar surface
area addresses intrinsic permeability problems while
maintaining simpler drug design and regulatory pathways.
Adjusting physicochemical properties is generally preferable
before introducing prodrug complexity that adds metabolic and
safety variables.
A: Prodrugs can be useful but introduce variable activation,
additional metabolic liabilities, and regulatory complexity; they
are not the default solution.
C: The statement conflates prodrug use with metabolic
instability; prodrugs are primarily used to improve delivery, not
PHARMACOLOGICAL BASIS OF
THERAPEUTICS
14TH EDITION
• AUTHOR(S)LAURENCE BRUNTON;
BJORN KNOLLMANN
TEST BANK
1⃣
Reference
Ch. 1 — Drug Discovery: From Medicinal Plants to Computer-
Aided Drug Design
Stem
A translational research team identifies a bioactive alkaloid
from a rainforest plant that shows potent inhibition of a cancer
cell line in vitro. As the team plans next steps, they must decide
between proceeding with isolation and derivatization of the
,natural product versus moving to high-throughput screening
(HTS) of synthetic libraries. Which approach best balances
target validation, chemical tractability, and the risk of later-
stage attrition?
Options
A. Prioritize isolation and systematic derivatization of the
natural product because natural-product scaffolds are
inherently drug-like and lower attrition.
B. Prioritize HTS of diverse synthetic libraries because HTS is
faster and more likely to yield high-affinity, patentable scaffolds.
C. Use the natural product as a pharmacophore template to
perform structure–activity guided optimization plus parallel
screening of small focused libraries.
D. Abandon the natural product and perform phenotypic
screening on unrelated cell lines to find better starting points.
Correct answer
C
Rationales
Correct (C): Combining the natural product as a pharmacophore
template with focused library screening preserves the validated
biological activity while addressing chemical tractability and
patentability. This hybrid strategy leverages structure–activity
relationships (SAR) to optimize potency and ADMET while
reducing the risk of developing an intractable scaffold.
A: Overstates the assumption that natural scaffolds are always
drug-like; many natural products have poor bioavailability or
,synthetic accessibility, increasing attrition.
B: HTS alone ignores the validated bioactivity and may produce
hits that lack the natural product’s mechanistic relevance; also,
HTS hits often require heavy optimization.
D: Abandoning a validated bioactive compound sacrifices
known mechanism and increases development risk; phenotypic
screens are useful but not a reason to discard a validated lead.
Teaching point
Natural products + pharmacophore-guided optimization
combine validation with chemical tractability.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
2️⃣
Reference
Ch. 1 — Drug Discovery: From Medicinal Plants to Computer-
Aided Drug Design
Stem
A biotech firm uses target-based screening against a kinase
implicated in inflammatory disease. Several nanomolar
inhibitors are discovered, but cellular efficacy is poor due to
limited cell permeability. The medicinal chemist suggests
designing prodrugs to improve intracellular delivery. Evaluate
, the appropriateness of a prodrug strategy versus optimizing
physicochemical properties directly.
Options
A. Prodrug design is preferable because it bypasses the need to
modify the active pharmacophore, preserving potency.
B. Directly optimizing lipophilicity and polar surface area of the
active compound is preferable to improve permeability and
avoid prodrug complexity.
C. Use a prodrug only if the compound is rapidly metabolized;
otherwise, modify the target instead.
D. Abandon small-molecule approaches and pursue monoclonal
antibodies against the kinase.
Correct answer
B
Rationales
Correct (B): Direct optimization of lipophilicity and polar surface
area addresses intrinsic permeability problems while
maintaining simpler drug design and regulatory pathways.
Adjusting physicochemical properties is generally preferable
before introducing prodrug complexity that adds metabolic and
safety variables.
A: Prodrugs can be useful but introduce variable activation,
additional metabolic liabilities, and regulatory complexity; they
are not the default solution.
C: The statement conflates prodrug use with metabolic
instability; prodrugs are primarily used to improve delivery, not
